Adagene Q4 2025 Earnings Report

Adagene EPS Results

• Actual EPS: -$0.04
• Consensus EPS: -$0.28
• Beat/Miss: Beat by +$0.24
• One Year Ago EPS: N/A

Adagene Revenue Results

• Actual Revenue: $3.84 million
• Expected Revenue: $17.50 million
• Beat/Miss: Missed by -$13.66 million
• YoY Revenue Growth: N/A

Adagene Announcement Details

• Quarter: Q4 2025
• Date: 4/1/2026
• Time: Before Market Opens
• Conference Call Date: Wednesday, April 1, 2026
• Conference Call Time: 7:00AM ET

Adagene (NASDAQ:ADAG) Inc., headquartered in Suzhou, China, is a clinical-stage biopharmaceutical company specializing in the discovery and development of antibody-based therapeutics for cancer and immune-related diseases. Founded in 2017, the company leverages its proprietary immunome technology platform to mine human antibody repertoires and engineer novel monospecific and bispecific antibodies. Adagene’s pipeline includes multiple candidates in preclinical and early clinical development, with a focus on targeting tumor microenvironments and modulating immune checkpoints to enhance anti-tumor efficacy.

At the core of Adagene’s research and development efforts is its Bihanc™ antibody platform, which combines combinatorial phage display, structure-based design and artificial intelligence to optimize binding affinity, specificity and developability. The immunome platform enables rapid identification of high-quality antibody candidates derived from healthy donor B cells, while the AI-driven design engine accelerates selection and engineering, aiming to streamline candidate advancement toward investigational new drug filings and clinical trials.

Adagene operates research facilities in Suzhou and maintains an office in Cambridge, Massachusetts, serving global markets through strategic collaborations with leading pharmaceutical partners. The company’s leadership team is led by founder and CEO Dr. Ying Yan, whose expertise in antibody discovery and immuno-oncology has driven the development of its platform-based strategy. Under her guidance, Adagene has expanded its research capabilities and advanced multiple therapeutic candidates into the clinic.